Dr. Sharyn Lewin discusses how germline testing helps guide treatment decisions.
Dr. Gregory Vidal discusses how germline testing differs from tumor testing and how germline results can inform eligibility for treatment options.
PARPi can cut risk of disease progression or death up to 46% for HER2-negative metastatic breast patients with gBRCA mutation1
PARPi can cut risk of disease progression or death up to 70% for ovarian cancer patients with a gBRCA mutation2
PARPi can cut risk of disease progression or death up to 47% for pancreatic cancer patients with a gBRCA mutation3
PARPi can cut risk of disease progression or death up to 46% for HER2-negative metastatic breast patients with gBRCA mutation1
PARPi can cut risk of disease progression or death up to 70% for ovarian cancer patients with a gBRCA mutation2
PARPi can cut risk of disease progression or death up to 47% for pancreatic cancer patients with a gBRCA mutation3
Identifying patients who meet criteria has become easier than ever with simple indications for affected patients
97%
75% ≥ 90%
100%
*Patients who are recipients of US government funded programs such as Medicaid, Medicare, Medicare-Advantage and Tricare may not be eligible for MFAP
Myriad myRisk has an industry leading turnaround time of 14 days or less on average with no reflex ordering required.
Myriad myRisk STAT for Pancreatic Cancer can give you faster results for patients who may become eligible for a PARP inhibitor:
Myriad is the industry leader in providing accurate results for patients. Through our unique, clinically validated techniques, Myriad provides answers other labs cannot25-28.
Myriad provides a comprehensive report and Medical Management Tool (MMT) for every patient who undergoes a myRisk test regardless of result. The MMT incorporates a comprehensive report of the genes tested and a summary of society guidelines to optimize your patient's medical management.
As variants are reclassified, you will receive amended reports automatically as a part of Myriad's lifetime commitment to you and your patients.